Formycon AG (FYB.DE)
XETRA · EUR · Healthcare · Biotechnology
€19.04 (+0.74%) as of
Key statistics
- Forward P/E
- 17.20
- EPS (TTM)
- -1.42
- Dividend yield
- 0.00%
- 52-week range
- 15.80 – 26.95
- Beta
- 0.70
- Revenue (TTM)
- 61.24M
- Profit margin
- -41.04%
- Analyst target
- €41.20
- Volume
- 718.00
About Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company's pipeline includes ustekinumab used in the treatment of Crohn's disease, ulcerative colitis, Plaque Psoriasis, and Psoriatic Arthritis under the Otulf, Fymskina, and Sitovab brand names. It is also developing pembrolizumab for the treatment of immuno-oncology diseases, such as advanced melanoma, non-small cell bronchial carcinoma, asthma, hodgkin's lymphoma, urothelial carcinomas, tumors in the head and neck area, sinusitis with nasal polyps area, other tumor and genetic diseases; and FYB208 and FYB209 that is indicated for immunology areas. Formycon AG has cooperation agreements with Biocelys S.A. and Santo Biosimilar GmbH in connection with a biosimilar candidate. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Planegg, Germany
- Employees
- 196
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.